Mithra enters deal to commercialize Tibelia in Chile

5 March 2019

Adding to a string of licensing deals, Belgian women’s health care company Mithra Pharmaceuticals (Euronext Brussels: MITRA) today revealed that it has entered into a license and supply agreement with Saval Pharmaceuticals to commercialize Tibelia (tibolone), a generic version of US pharma giant Merck & Co’s (NYSE: MRK) Livial in Chile.

Tibolone is a synthetic steroid that relieves postmenopausal symptoms and prevents osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products.

Saval Pharmaceuticals, a leading pharmaceutical company based in Chile, offers a wide range of innovative and high quality pharmaceutical products to various countries in Latin America, designed to improve public health outcomes. Under the terms of the seven-year agreement, Saval will distribute Tibelia in Chile, which has a tibolone market worth approximately 3.2 million euros ($3.6 million) per year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK